Datamonitor Healthcare CNS Disease Analysis: Schizophrenia

March 31, 2021

There have been a number of recent impactful events in the schizophrenia space. In late 2020, Minerva released mixed results for its negative symptom prospect, MIN-101, that have plunged the drug’s potential into uncertainty. In addition, Alkermes’ Lybalvi was well received in an FDA advisory committee meeting in October 2020; however, the FDA’s subsequent issuance of a complete response letter (based on a manufacturing issue) has postponed likely approval.

The current dynamics of the antipsychotic market show domination by atypical antipsychotics, typically oral agents, but there is an increasing uptake of long-acting injectable (LAI) neuroleptics, which will continue. Oral atypical antipsychotics that were historical blockbusters are now facing intense generic erosion. The highest-selling oral antipsychotic is Latuda, one of the newer atypical drugs, but its market exclusivity is only set to last until 2023.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered:

Schizophrenia